The acquisition of Selcia provides Eurofins with an entry into the custom radiolabelling and innovative pre-clinical, integrated drug discovery services markets, both exciting new business streams for Eurofins offering significant growth potential.
Klaus Kuegler, Senior VP of Eurofins Agroscience Services Group, said: “We are extremely pleased to welcome Selcia to the Eurofins Group. Selcia’s focus on quality and world leading carbon-14 (14C) radiolabelling capabilities, including GLP analytical and GMP API manufacturing, fills a strategic gap in Eurofins’ global offering in the highly attractive pharmaceutical and agroscience testing markets.”
“In addition, Selcia provides Eurofins with integrated drug discovery services including medicinal chemistry and a unique peptidyl prolyl isomerase (PPIase) inhibitor screening platform. We look forward to supporting Selcia’s growth by providing access to the full range of services and capabilities of the Eurofins Group.”
Clive Cornell, COO at Selcia, said: “We are excited to become an integral part of the Eurofins Group. The acquisition will help Selcia invest and grow to meet the increasing global demand for high quality, 14C radiolabelled compounds.”
“Importantly Selcia will continue to independently foster relationships with new and existing customers as well as with Eurofins’ worldwide network of laboratories. The acquisition enables Eurofins Pharma Discovery Services to provide a more comprehensive offering of integrated drug discovery services including innovative hit to lead and lead optimisation medicinal chemistry, assay development and screening.”
Selcia acknowledges the help and support of InterPharmaLink, Basel, in facilitating the transaction.
